Please assess the completion status of the following clinical trial:

Trial Title: Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects, ≥ 40 and less than 85 years of age~2. Clinical diagnosis of at least moderate COPD as defined by the Global Initiative for Obstructive Lung Disease (GOLD) criteria (53):~   * Post bronchodilator FEV1/FVC \< 70% (Forced expiratory volume in 1 second/ forced vital capacity),~  * Post bronchodilator FEV1 \< 80% predicted, with or without chronic symptoms (i.e., cough, sputum production).~3. Cigarette consumption of 10 pack-years or more. Patients may or may not be active smokers.~4. To enrich the population for patients who are more likely to have acute exacerbations (54), each subject must meet one or more of the following 4 conditions:~   * Have a history of receiving a course of systemic corticosteroids and/or antibiotics for respiratory problems in the past year,~  * Visiting an Emergency Department for a COPD exacerbation within the past year, or~  * Being hospitalized for a COPD exacerbation within the past year~  * Be using or be prescribed supplemental oxygen for 12 or more hours per day~  * Willingness to make return visits and availability by telephone for duration of study.~Exclusion Criteria:~1. A diagnosis of asthma established by each study investigator on the basis of the recent American Thoracic Society/European Respiratory Society and National Institute for Health and Care Excellence guidelines.~2. The presence of a diagnosis other than COPD that results in the patient being either medically unstable, or having a predicted life expectancy \< 2 years.~3. Women who are at risk of becoming pregnant during the study (pre-menopausal) and who refuse to use acceptable birth control (hormone-based oral or barrier contraceptive) for the duration of the study.~4. Current tachy or brady arrhythmias requiring treatment~5. Presence of a pacemaker and/or internal cardioverter/defibrillator~6. Patients with a history of second or third degree (complete) heart block, or sick sinus syndrome~7. Baseline EKG revealing left bundle branch block, bifascicular block, ventricular tachyarrhythmia, atrial fibrillation, atrial flutter, supraventricular tachycardia (other than sinus tachycardia and multifocal atrial tachycardia), or heart block (2nd degree or complete)~8. Resting heart rate less than 65 beats per minute, or sustained resting tachycardia defined as heart rate greater than 120 beats per minute.~9. Resting systolic blood pressure of less than 100mm Hg.~10. Subjects with absolute (Class 1) indications for beta-blocker treatment as defined by the combined American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Guidelines which include myocardial infarction, acute coronary syndrome, percutaneous coronary intervention or coronary artery bypass surgery within the prior 3 years and patients with known congestive heart failure defined as left ventricular ejection fraction \<40%.(29, 30)~11. Critical ischemia related to peripheral arterial disease.~12. Other diseases that are known to be triggered by beta-blockers or beta-blocker withdrawal including myasthenia gravis, periodic hypokalemic paralysis, pheochromocytoma, and thyrotoxicosis~13. Patients on other cardiac medications known to cause atrioventricular (AV) node conduction delays such as amiodarone, digoxin, and calcium channel blockers including verapamil and diltiazem as well as patients taking clonidine.~14. Hospitalization for uncontrolled diabetes mellitus or hypoglycemia within the last 12 months.~15. Patients with cirrhosis~16. A clinical diagnosis of bronchiectasis defined as production of \> one-half cup of purulent sputum/day.~17. Patients otherwise meeting the inclusion criteria will not be enrolled until they are a minimum of four weeks from their most recent acute exacerbation (i.e., they will not have received a course of systemic corticosteroids, an increased dose of chronically administered systemic corticosteroids, and/or antibiotics for an acute exacerbation for a minimum of four weeks).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- Metoprolol succinate (Type: ACTIVE_COMPARATOR): Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).
- Placebo (Type: PLACEBO_COMPARATOR): Matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).